Seres Therapeutics, Inc.(MCRB)

Description: Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Antibiotics Autoimmune Disease Clinical Development Ulcer Ulcerative Colitis Inflammatory Bowel Disease Diarrhea Colitis Digestive Diseases Antimicrobial Resistance Cdi Clostridioides Difficile Clostridium Difficile Infection Clostridium Difficile

---

Home Page: www.serestherapeutics.com

MCRB Technical Analysis

200 Sidney Street
Cambridge, MA 02139
United States
Phone: 617 945 9626

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)